- Home
- ADAP
as 05-22-2025 12:30pm EST
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 75.5M | IPO Year: | 2015 |
| Target Price: | $1.52 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.20 - $1.48 | Next Earning Date: | 05-13-2025 |
| Revenue: | $179,639,000 | Revenue Growth: | 878.53% |
| Revenue Growth (this year): | -74.96% | Revenue Growth (next year): | 52.49% |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
GuruFocus.com
8 days ago
Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...
Newsfile
9 days ago
Adaptimmune Reports Q1 Financial Results and Provides Business Update
GuruFocus.com
10 days ago
What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings
Newsfile
15 days ago
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
Zacks Small Cap Research
2 months ago
ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story
GuruFocus.com
2 months ago
Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result
GuruFocus.com
2 months ago
Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...
Zacks Small Cap Research
2 months ago
ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options
Compare ADAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.